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pathway (Bodmer et al., 2000). Bax is required for TRAIL-
induced apoptosis of certain cancer cell lines possibly
by allowing release of second mitochondria-derived ac-
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The soluble recombinant TRAIL is of interest for can-Juntendo University School of Medicine
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ministration of soluble recombinant TRAIL in experimen-New York, New York 10021
tal animals, including mice and primates, induced
significant tumor regression without systemic toxicity
(Walczak et al., 1999; Ashkenazi et al., 1999). Not allThe TNF-related apoptosis-inducing ligand (TRAIL) of-
cancer cells are sensitive to the cytotoxic effects offers great promise as a cancer therapeutic. Initially,
TRAIL. DR5 mutations have been found in some cancerssoluble recombinant versions of the TRAIL molecule
of the head and neck, breast and lung, and Hodgkin’shave exhibited specific tumoricidal activity against a
lymphoma (El-Deiry, 2001), and recent studies in thevariety of tumors alone, or in combination with other
mouse suggest TRAIL immunoselects tumors for TRAILcancer treatments, and much anticipation awaits the
resistance (Takeda et al., 2002) (see below). DR5 hasoutcomes from early clinical trials. More recently, the
been implicated in the cellular response to DNA-damag-natural role of TRAIL has been explored in tumor and
ing radiation or chemotherapy as a target of p53 (Wu etallogeneic bone marrow transplantation models in the
al., 2000). Although one of the attractive features ofmouse. Strikingly, the TRAIL effector pathway appears
TRAIL is its ability to kill cancers with mutations in thea vital component of immunosurveillance of spontane-
p53 gene, the combination of TRAIL with chemothera-ous or resident tumor cells by both T cells and NK
peutic agents has been found to be particularly effectivecells, stimulating more hope that manipulating TRAIL
in killing cancers with wild-type p53, presumablyactivity is a natural path to improved cancer immuno-
through induction of DR5 expression (Nagane et al.,therapy.
2001). In addition, Bax mutation in mismatch repair-
deficient tumors can cause resistance to TRAIL therapy,TRAIL—A Promising Cancer Therapeutic
but preexposure to chemotherapy rescues tumor sensi-Members of the tumor necrosis factor (TNF) family of
tivity (LeBlanc et al., 2002). Synergy between TRAIL andcytokines are expressed by effector lymphocytes and
anticancer drugs has been demonstrated against di-
are important mediators of apoptosis that both shape
verse tumor cell types in tumor xenograft experiments.
and regulate the immune system. TNF-related apopto-
While data showing the impressive selective anti-tumor
sis-inducing ligand (TRAIL), also known as Apo2 ligand, activity in vitro of soluble TRAIL have generated consid-
is a type II transmembrane protein belonging to the TNF erable excitement and have resulted in the development
superfamily (Wiley et al., 1995; Pitti et al., 1996). At least of TRAIL as a novel anti-cancer agent, only now have
five receptors for TRAIL have been identified in humans a few key studies addressed the natural role of TRAIL
(only one, DR5 [TRAIL-R2] in mice) and two of them, in immunity against cancer.
DR4 (TRAIL-R1) and DR5, are capable of transducing an TRAIL Expression—A Clue to Its Natural Role?
apoptotic signal (Degli-Esposti, 1999; Ashkenazi, 2002). Three experimental tools have been key in defining the
The other three receptors (TRAIL-R3, TRAIL-R4, and expression and physiological role of TRAIL in mice, in-
a soluble receptor called osteoprotegerin [OPG,TRAIL- cluding (1) a neutralizing anti-mouse (m)TRAIL mono-
R5]) lack death domains but may serve as decoy recep- clonal antibody (mAb) (N2B2) (Kayagaki et al., 1999c);
tors to regulate TRAIL-mediated cell death. Investiga- (2) soluble recombinant human DR5 (Song et al., 2000);
tion of the intracellular signaling pathways responsible and (3) TRAIL gene-targeted mice (Cretney et al., 2002).
for TRAIL receptor-induced apoptosis has produced Although TRAIL mRNA has been found in a variety of
controversial results, but most recent studies suggest tissues and cells (Wiley et al., 1995), the anti-mTRAIL
DR5 signals through a FADD- and caspase-8-dependent mAb has been extremely useful in determining which
cells express TRAIL constitutively, and following activa-
tion. From studies in both mice and humans, we can*Correspondence: m.smyth@pmci.unimelb.edu.au
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B cells, dendritic cells (DC), monocytes, or NK cells do cell activation and IFN- production. Thus, although the
not express a detectable level of TRAIL on their surface only NK cell subset to express TRAIL constitutively is
(Takeda et al., 2001; Smyth et al., 2001; Kayagaki et al., found in the liver, many NK cells in the lung, liver, and
1999c; Griffith et al., 1999; Fanger et al., 1999). The spleen were induced to express TRAIL and thereby kill
exception appears to be a subset of mouse liver NK tumor cells in vivo (Smyth et al., 2001). In all cases,
cells that express TRAIL constitutively in a type II neutralization of TRAIL additively enhanced liver metas-
IFN-dependent manner (Takeda et al., 2001; Smyth et tasis in perforin-deficient mice but not in IFN--deficient
al., 2001). It appears most likely that TRAIL expression mice (Smyth et al., 2001). These findings clearly place
on liver NK cells is regulated by IFN- secreted from perforin and TRAIL as the two key cytotoxic effector
NK cells in an autocrine manner, since a substantial pathways used by NK cells.
proportion of liver NK cells constitutively produce both TRAIL-Mediated Immunosurveillance
TRAIL and IFN- in wild-type and T cell-deficient mice of Cancer Initiation
(Takeda et al., 2001). The presence of a minor population Immune surveillance against tumors is mediated by both
of TRAIL IFN-– cells suggests the contribution of some innate and adaptive components of cellular immunity.
other mechanism. The exclusive constitutive expression The adaptive component mainly consists of CD8 cyto-
of TRAIL on some liver NK cells raises the issue of what toxic T lymphocytes (CTL) that recognize tumor antigens
normal physiological role TRAIL may play in the liver. It presented by major histocompatibility complex (MHC)
is possible that liver NK cells may express TRAIL in class I molecules on tumor cells. NK cells have long been
response to gut-derived endogenous endotoxin or in
implicated in innate immunity against tumors, especially
early responses to infections, although analysis of germ-
MHC class I-deficient variants. Recent studies have sub-free mice revealed a subset of liver NK cells expressing
stantiated a pivotal role of NK cells, perforin, and IFN-TRAIL (K.T., unpublished data). Alternatively, a current
in natural protection from primary tumor developmenthypothesis from the study of human NK cells is that
induced by a chemical carcinogen methylchoranthreneimmature NK cells express TRAIL and lose expression
(MCA) (Street et al., 2001) (Figure 1c). Neutralization ofwith maturity into granulated NK cells exerting perforin
TRAIL promoted tumor development in mice inoculatedand FasL-mediated cytotoxicity (Zamai et al., 1998). Fur-
with MCA and this protective effect of TRAIL was atther studies will be required to determine whether
least partly mediated by NK cells and totally dependentmouse liver NK cells constitutively expressing TRAIL
on IFN- (Takeda et al., 2002; Cretney et al., 2002). Het-represent a distinct immature subset or stage of NK cell
erogeneous tumor cells with different TRAIL sensitivitydifferentiation. TRAIL is highly expressed on most NK
are expected to arise during the MCA-induced tumorcells after stimulation with IL-2, IFNs, or IL-15 (Kayagaki
development in individual mice; however, the preferen-et al., 1999a, 1999c; Zamai et al., 1998; Sato et al., 2001).
tial emergence of TRAIL-sensitive fibrosarcoma cells inSimilarly, type I IFN-activated human peripheral blood
TRAIL-deficient and IFN--deficient mice strongly sug-T cells (Kayagaki et al., 1999b), CD11c DC, and mono-
gested an immunoselection pressure against TRAIL-cytes express TRAIL (Fanger et al., 1999; Griffith et al.,
sensitive cells during tumor development (Takeda et1999). These expression patterns reflect the broad role
al., 2002) (Figure 1c). In summary, IFN- may regulatethat TRAIL likely plays in innate immune responses in-
volving IFNs, NK cells, and DC. TRAIL-mediated tumor surveillance, not only by regulat-
TRAIL—A Key Anti-Metastatic Effector Molecule ing TRAIL expression on effector cells but also by sensi-
of NK Cells tizing tumor cells to TRAIL-mediated cytotoxicity. The
TRAIL was shown to be involved in the cytotoxic activity mechanism by which IFN- sensitizes tumor cells to
of activated NK cells against TRAIL-sensitive tumor cells TRAIL remains to be determined. A substantial contribu-
in vitro (Kayagaki et al., 1999c) and, along with perforin tion of TRAIL to immune surveillance against spontane-
and FasL, partly responsible for spontaneous NK cell ous tumor development caused by p53 mutation was
activity against TRAIL-sensitive lines (Takeda et al., also recently demonstrated (Takeda et al., 2002). In con-
2001). The anti-metastatic function of NK cells against trast to perforin that selectively protected from dissemi-
TRAIL-sensitive tumor cells in mice was also shown to nated lymphoma (Smyth et al., 2000), TRAIL, like IFN-,
be partly dependent upon TRAIL, and natural TRAIL additionally suppressed sarcoma formation. Collec-
anti-metastatic activity was restricted to liver NK cells tively, these studies demonstrated a role for TRAIL in
in several different models (Takeda et al., 2001) (Figure
NK cell-mediated immunosurveillance against tumors.
1a). Both neutralizing anti-mTRAIL mAb and TRAIL
Since monocytes and DC also express TRAIL after stim-gene-targeted mice supported a direct role for NK cell
ulation with IFNs, a possible contribution of TRAIL onTRAIL in natural suppression of tumor metastasis, with
these cells to anti-tumor activity in vivo must now beno phenotype observed against all TRAIL-resistant cell
evaluated. In particular, some tumor models already ex-lines examined in vivo (Takeda et al., 2001; Cretney et
amined (Takeda et al., 2002) have suggested that TRAILal., 2002). These findings provided evidence for the
expressed on non-T/NK cells might contribute to thephysiological function of TRAIL as a tumor suppressor.
natural suppression of liver metastasis, although theIFN--mediated TRAIL induction on NK cells was also
identity of these effector cells remains unclear. Tumorsshown to play a significant role in IFN--dependent anti-
where IFN- and monocytes control tumor growth aremetastatic effects of IL-12 and the NKT cell activator,
worthy of further attention. Further studies on the molec--galactosylceramide (-GalCer) in the liver, lung, and
ular mechanisms by which IFNs and TRAIL contributemammary gland (Smyth et al., 2001; Cretney et al., 2002)
to immune surveillance against tumors may provide a(Figure 1b). Therefore, TRAIL may be involved in the anti-
tumor effects of many cytokines that act to stimulate NK novel strategy to prevent tumor development.
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Figure 1. The Role of TRAIL-Mediated Cyto-
toxicity in Tumor Suppression by NK Cells
(A) TRAIL-mediated anti-metastatic effect by
liver NK cells. Mouse liver NK cells express
TRAIL constitutively and they are responsible
for the anti-metastatic function against
TRAIL-sensitive tumor cells. The TRAIL ex-
pression on liver NK cells is regulated by en-
dogenously produced IFN-.
(B) Relative contribution of TRAIL-mediated
cytotoxicity by NK cells in IFN--inducing im-
munotherapies. During effective immuno-
therapy with IL-12 or -GalCer, the induction
of IFN- controls tumor metastasis by virtue
of TRAIL induction on NK cells. IL-2 and IL-
15 may also induce TRAIL on NK cells and
stimulate NK cell proliferation.
(C) Model of role for TRAIL in immune surveil-
lance against tumor development. Both NK
cells and IFN- have been implicated in natu-
ral protection from primary tumor develop-
ment. TRAIL is partly responsible for the NK-
cell-mediated and IFN--dependent mecha-
nism of tumor elimination. Type I IFNs also
induce TRAIL expression on NK cells. NK cell
activation is strictly regulated by positive and
negative signals through NK cell activating
receptors (NKR) and killer inhibitory receptors
(KIR), respectively. NK cells recognize some
ligands on transformed cells and then are ac-
tivated to eliminate transformed (“danger-
ous”) cells in a TRAIL-dependent manner.
Graft versus Tumor—Contribution of T Cell TRAIL cells (graft versus tumor, GVT) provides arguably (a) the
best evidence for T cell-mediated anti-tumor activityAlthough several years ago activated T cells were shown
to exert cytolysis of target cells through the TRAIL path- with clinical relevance and (b) is at present the most
potent immunotherapy of cancer available. GVT activityway (Kayagaki et al., 1999b), only now has a clear role
for TRAIL in the T cell-mediated immune defense against is triggered by the recognition of tumor-specific anti-
gens or alloantigens expressed on malignant cells, andtumor been formally shown (Schmaltz et al., 2002) (Fig-
ure 2). Allogeneic hematopoietic cell transplantation thus graft versus host (expressing alloantigens) disease
(GVHD), involving systemic illness and target organ(AHCT) is an important therapy for a variety of malignant
diseases. The anti-tumor activity of allogeneic donor T damage to skin, liver, and intestines, is the single most
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Figure 2. Role of TRAIL on Allo-Reactive T
Cells in Graft versus Host Disease and Graft
versus Tumor Activity after Allogeneic Hema-
topoietic Cell Transplantation
The reactivity of the donor T cell against re-
cipient normal cells and transformed (leuke-
mia) cells is essential in the development of
GVHD and GVT. Cytolytic activity of donor T
cells is mediated through different effector
mechanisms in those responses. The Fas/
FasL and perforin pathways are mainly re-
sponsible for donor T cell-mediated GVHD
activity. The perforin pathway plays an impor-
tant role in GVT activity. TRAIL on donor T
cells is selectively required for optimal GVT
activity, but not for GVHD.
important complication of AHCT. In three different in allo-BMT therapy must be balanced by the knowledge
that many leukemias (ALL, AML) from patients are notmouse bone marrow transplantation (BMT) models,
TRAIL has been shown to be required for optimal GVT sensitive to TRAIL in vitro (Wuchter et al., 2001) and
thus combination therapies may need to be assessed.activity by donor T cells (Schmaltz et al., 2002). By con-
trast, TRAIL played little or no role in the GVHD activity A Role for TRAIL-Mediated Anti-Tumor Immunity
in Humans?of donor T cells and the TRAIL pathway was not required
for GVHD target organ pathology. Given that TRAIL- A recent paper has reported that TRAIL expression is
lower on CD4 lymphocytes from patients with ad-deficient T cells have an intact proliferative and cytokine
response to mitogen and alloantigens in vitro and in vivo, vanced melanoma and immune cells that can express
TRAIL are observed in regressing primary melanomathese data may represent a very important biological
illustration that the TRAIL pathway can selectively kill and in metastases of patients responding to IFN-2 ther-
apy (Hersey and Zhang, 2001). In addition, TRAIL ex-transformed cells preferentially over normal cells. Donor
CD8 T cells expressing perforin mediate GVT, and pression was upregulated on CD56 NK cells in the
peripheral blood of hepatocellular carcinoma patientsCD4 or CD8 T cells expressing FasL and/or perforin
cause GVHD (Schmaltz et al., 2001). TRAIL expression responding to a combination of 5-fluorouracil and IFN-
(H.Y., unpublished data). While such findings are inter-has been detected in both CD4 and CD8 T cells after
allogeneic stimulation in vitro or in vivo. This illustration esting, they are too preliminary to make a general con-
clusion. Comparing the TRAIL expression on immuneof natural TRAIL activity is supported by the ability of
recombinant TRAIL to reduce the numbers of myeloid cells from patients with different prognoses may be of
limited value and similar attempts to correlate the levelscolonies from patients with acute myeloid leukemia
(AML), chronic myeloid leukemia (CML), and myelodys- of other effector molecules such as perforin/granzyme
and FasL with cancer progression have not yet beenplastic syndromes, but not from normal BM (Plasilova
et al., 2002). In the context of other molecules of the particularly informative. Some human cancer cell lines
and primary human epithelial tumors are sensitive toTNF/TNFR superfamilies, implicated in GVHD and GVT,
a rational therapeutic strategy will now be to minimize TRAIL-induced apoptosis ex vivo; however, significant
heterogeneity in TRAIL sensitivity has been reported forGVHD by neutralizing the FasL/Fas pathway and en-
hance GVT by augmenting the TRAIL/TRAIL-R pathway. a variety of human cancers. It remains to be proven
whether the immune system does have a significantAlthough type I IFN stimulate TRAIL in vitro, it is unclear
whether cotreatment with type I IFN in vivo may further impact on epithelial malignancy in humans and therefore
one might not expect such human tumors to be TRAILenhance the GVT benefit of TRAIL. With the recent dem-
onstration in allo-BMT models that NK cell allo-trans- resistant. In human tumor types that are recognized as
immunogenic, such as melanoma, it is clear that manyplants mismatched at KIR can enhance GVT and mini-
mize GVHD, it is quite likely that part of the success of fresh isolates from patients are indeed TRAIL resistant
and this resistance appeared to be associated with lowthis approach similarly relies on the selectivity of TRAIL
for transformed cells. Alternatively, it is also possible TRAIL receptor expression (Nguyen et al., 2001). Tumors
have many ways to escape immune surveillance withoutthat mismatched NK cells might eliminate bone marrow-
derived antigen-presenting cells by a TRAIL-dependent needing to become TRAIL resistant and in the human,
non-death-inducing TRAIL-R expressed on normal cellsmechanism, thereby preventing these cells from pre-
senting recipient antigens to grafted T cells and thus may confer protection from TRAIL during malignant
transformation. The isolation of patients genetically de-limiting GVHD. This enthusiasm for TRAIL as a therapy
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Fanger, N.A., Maliszewski, C.R., Schooley, K., and Griffith, T.S.fective in TRAIL or TRAIL-R expression may or may not
(1999). Human dendritic cells mediate cellular apoptosis via tumorreveal a cancer-susceptible phenotype (like FasL-Fas);
necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp.however, no such condition has yet been reported.
Med. 190, 1155–1164.
Manipulation of TRAIL function in humans has not yet
Griffith, T.S., Wiley, S.R., Kubin, M.Z., Sedger, L.M., Maliszewski,
been addressed in any clinical setting. We now await the C.R., and Fanger, N.A. (1999). Monocyte-mediated tumoricidal activ-
administration of recombinant human TRAIL to cancer ity via the tumor necrosis factor-related cytokine TRAIL. J. Exp.
patients, but additional trials comparing the efficacy of Med. 189, 1343–1354.
TRAIL-expressing NK cells and T cells in humans follow- Hersey, P., and Zhang, X.D. (2001). How melanoma cells evade trail-
ing adoptive transfer in either solid tumor or allo-BMT induced apoptosis. Nat. Rev. Cancer 1, 142–150.
transplant settings may also be of interest. Recombinant Hilliard, B., Wilmen, A., Seidel, C., Liu, T.S., Goke, R., and Chen, Y.
(2001). Roles of TNF-related apoptosis-inducing ligand in experi-forms of TRAIL have been shown to kill tumor cells in
mental autoimmune encephalomyelitis. J. Immunol. 166, 1314–1319.either a type I (not protected by bcl-2 family proteins)-
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang,and II (protected by bcl-2 family proteins)-dependent
H., Mountz, J.D., Koopman, W.J., Kimberly, R.P., et al. (2001). Tu-manner. These different forms of target cell sensitivity
moricidal activity of a novel anti-human DR5 monoclonal antibodyare not well understood molecularly and which of these
without hepatocyte cytotoxicity. Nat. Med. 7, 954–960.
pathways is used by natural TRAIL expressed on lym-
Kayagaki, N., Yamaguchi, N., Nakayama, M., Eto, H., Okumura, K.,phocytes remains unclear. Defining the contexts in
and Yagita, H. (1999a). Type I interferons (IFNs) regulate tumor ne-
which TRAIL may eliminate or spare normal tissues is crosis factor-related apoptosis-inducing ligand (TRAIL) expression
also of great importance when considering manipulating on human T cells: a novel mechanism for the antitumor effects of
type I IFNs. J. Exp. Med. 189, 1451–1460.the TRAIL pathway in novel cancer therapies. The ability
of some soluble forms of TRAIL to kill normal cells such Kayagaki, N., Yamaguchi, N., Nakayama, M., Kawasaki, A., Akiba,
H., Okumura, K., and Yagita, H. (1999b). Involvement of TNF-relatedas hepatocytes (Lawrence et al., 2001), and the possible
apoptosis-inducing ligand in human CD4 T cell-mediated cytotox-role of TRAIL in other immune responses (Hilliard et al.,
icity. J. Immunol. 162, 2639–2647.2001; Song et al., 2000), raises some concerns about
Kayagaki, N., Yamaguchi, N., Nakayama, M., Takeda, K., Akiba, H.,simplistic approaches. The demonstrated killing activity
Tsutsui, H., Okamura, H., Nakanishi, K., Okumura, K., and Yagita, H.of anti-human DR5 mAbs against liver cancer cells, but
(1999c). Expression and function of TNF-related apoptosis-inducing
not normal hepatocytes (Ichikawa et al., 2001), at least ligand on murine activated NK cells. J. Immunol. 163, 1906–1913.
offers hope that rational engineering of recombinant
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D.,
molecules will provide new strategies to exploit the Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al.
TRAIL/TRAIL-R pathway in cancer cells. (2001). Differential hepatocyte toxicity of recombinant Apo2L/TRAIL
versions. Nat. Med. 7, 383–385.
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